SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses. "Five Prime fits squarely within Amgen's leading oncology portfolio and includes bemarituzumab, a Phase 3 tr

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The cancellation is the result of the company’s announcement on March 4, 2021 that it has entered into an agreement under which Amgen Inc. will acquire Five Prime Therapeutics. Five Prime will issue its fourth quarter and full-year 2020 financial results in its Form 10-K that it will file with the Securities and Exchange Commission. About Five Prime Therapeutics Five Prime is a clinical stage biotech

THOUSAND OAKS, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. This acquisition adds Five Prime’s innovative pipeline to Amgen’s leading oncology portfolio. Five Prime’s lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontl

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. This acquisition adds Five Prime's innovative pipeline to Amgen's leading oncology portfolio. (PRNewsfoto/Amgen) Five Prime's lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), will report its fourth quarter and full year 2020 operational and financial results on Wednesday, March 10, 2021 after the U.S. financial markets close. Five Prime will also host a conference call and live audio webcast that same day at 4:30 p.m. (ET) / 1:30 p.m. (PT) to provide a general business update and discuss the company’s financial results. The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (internatio

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the Cowen 41st Annual Health Care Conference on Thursday, March 4, 2021 at 10:30 a.m. ET / 7:30 a.m. PT. Live audio webcast of the presentation will be accessible and available for replay from the “Events & Presentations” section of the Company’s website at: http://investor.fiveprime.com/events.cfm. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conf

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the virtual SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 10:00 a.m. ET / 7:00 a.m. PT. Live audio webcast of the presentation will be accessible and available for replay from the “Events & Presentations” section of the Company’s website at: http://investor.fiveprime.com/events.cfm. Five Prime will maintain an archived replay of the webcast on its website fo

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer, are scheduled to participate in a fireside chat at the virtual Guggenheim Healthcare Talks: Oncology Day on Friday, February 12, 2021 at 1:00 p.m. ET/10:00 a.m. PT. Live audio webcast of the fireside chat will be accessible and available for replay from the “Events & Presentations” section of the Company’s website at: http://investor.fiveprime.com/events.cfm. Five Prime will maintain an archived replay of the webcast on its website for 30 days aft

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced clinical results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer. Trial results were presented in a late-breaking oral presentation today by UCLA Health’s Zev Wainberg, M.D., at the 2021 ASCO Gastrointestinal Cancers Virtual Annual Symposium (ASCO GI). The ASCO GI presentation slides are available on the company’s website. The FIGHT trial evaluated bemarituzumab plus chemotherapy (mFOLFOX6) versus placebo plus chemotherapy in

SC 13D - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

SC 13G/A - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

SC 13G - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

SC 13G - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

SC 13G - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

SC 13G - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

Guggenheim resumed coverage of Five Prime Therapeutics with a rating of Neutral and set a new price target of $38.00

Jefferies Financial Group resumed coverage of Five Prime Therapeutics with a rating of Hold and set a new price target of $38.00

Guggenheim downgraded Five Prime Therapeutics from Buy to Neutral and set a new price target of $38.00

Guggenheim downgraded Five Prime Therapeutics from Buy to Neutral

Jefferies downgraded Five Prime Therapeutics from Buy to Hold and set a new price target of $38.00

Jefferies Financial Group downgraded Five Prime Therapeutics from Buy to Hold

Wedbush downgraded Five Prime Therapeutics from Outperform to Neutral

Wells Fargo & Company downgraded Five Prime Therapeutics from Overweight to Equal Weight

SC 13G/A - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

15-12B - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

EFFECT - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)